Health Care & Life Sciences » Pharmaceuticals » Novartis | Novartis top drugs by revenue 2017

Novartis' top drugs based on revenue 2017

Novartis AG's top 10 drugs based on revenue in 2017 (Figures expressed in millions of U.S. dollars, unless otherwise specified)

The data illustrates Novartis AG's top 10 drugs based on revenue in 2017. Novartis is a Swiss-based global pharmaceutical company. In that year, Novartis' drug Tasigna generated some 1.84 billion USD of revenue. Since several years, Gleevec (glivec) is one of Novartis' top pharmaceutical product based on revenue. Gleevec is a drug for the treatment of several types of cancer.

Gilenya 3185
Cosentyx 2071
Gleevec/glivec 1943
Lucentis 1888
Tasigna 1841
Sandostatin 1612
Afinitor/Votubia 1525
Galvus 1233
Exjade 1059
Exforge 960

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.